PDF(Pubmed)
Abstract：
Background Helicobacter pylori infection has been identified to cause constantly recurring inflammation, leading to gastrointestinal tract disorders, including carcinoma. The standard triple therapy (STT), used to eradicate H. pylori, includes two antimicrobials and a proton pump inhibitor for two weeks. Other drug regimens have also been developed since H. pylori exhibits antimicrobial resistance. These regimens, including probiotics, have been shown to lower adverse drug reactions (ADR), improve drug adherence, exert bacteriostatic effect, and reduce inflammation. Objective This study intended to explore probiotic intervention for improving eradication rates and mitigating adverse effects while administrating STT. Methods This prospective study was conducted from May to December, 2021, in the Department of Gastroenterology of Ship International Hospital, Dhaka, Bangladesh, to observe the effects of probiotics inclusion along with STT on H. pylori eradication. A total of 100 patients aged ≥18 years who tested positive for H. pylori were included. The experimental group (n=50) was given STT and probiotics, and the control group (n=50) was given only STT without probiotics for 14 days. Necessary follow-up was done six weeks after treatment. An independent sample t-test, chi-square test, and multiple regression analysis were used for statistical analysis. Result The odds of getting rapid urease test (RUT) negative results from positive were 2.06 times higher (95%CI= 0.95, 3.22, p=0.054) in the experimental group. ADRs were crucially towering in the control group (p=0.045) compared to the probiotics group. The probiotics group had a lower risk of having adverse effects by 0.54 times (95%CI=0.19, 0.84, p=0.032) than the control group. Conclusion Using probiotics and STT together to eradicate H. pylori may lower ADR and improve treatment adherence. It may also help terminate H. pylori infection more effectively. More research is required as H. pylori is very contagious and can ultimately cause life-threatening gastric cancer.
摘要：
背景：幽门螺杆菌感染已被确定会引起不断复发的炎症，导致胃肠道疾病，包括癌症。标准三联疗法（STT），用于根除幽门螺杆菌，包括两种抗菌药物和一种质子泵抑制剂，为期两周。由于幽门螺杆菌表现出抗菌素耐药性,还开发了其他药物方案。这些方案，包括益生菌,已被证明可以降低药物不良反应（ADR），提高药物依从性，发挥抑菌效果，减少炎症。目的探讨益生菌干预对提高STT根除率和减轻不良反应的作用。方法本前瞻性研究于5月至12月进行。2021年，在船舶国际医院消化内科，达卡,孟加拉国,观察益生菌包合STT对幽门螺杆菌根除的影响。共纳入100名年龄≥18岁、幽门螺杆菌检测呈阳性的患者。实验组(n=50)给予STT和益生菌,对照组（n=50）仅给予STT，无益生菌14天。治疗后6周进行必要的随访。独立样本t检验，卡方检验,采用多元回归分析进行统计分析。结果实验组快速尿素酶试验（RUT）阴性结果阳性的几率是实验组的2.06倍（95CI=0.95、3.22，p=0.054）。与益生菌组相比，对照组的ADR至关重要（p=0.045）。益生菌组的不良反应风险比对照组低0.54倍（95CI=0.19，0.84，p=0.032）。结论联合使用益生菌和STT根除幽门螺杆菌可能会降低ADR并提高治疗依从性。它也可能有助于更有效地终止幽门螺杆菌感染。需要更多的研究，因为幽门螺杆菌非常具有传染性，最终可能导致危及生命的胃癌。
